---
title: "Sunshine Lake Pharma Backs RMB2 Billion Healthcare and AI Venture Fund"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290993657.md"
description: "Sunshine Lake Pharma announced the establishment of a RMB2 billion healthcare and AI venture fund with Shenzhen HEC Technology and Zhejiang HEC Health. Sunshine Lake will contribute RMB500 million (25%) as a limited partner, while HEC partners provide RMB1.5 billion and manage the fund. The 12-year partnership aims to invest in unlisted healthcare and biomedicine companies, enhancing Sunshine Lake's strategic positioning in China's biomedical sector."
datetime: "2026-06-26T15:19:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290993657.md)
  - [en](https://longbridge.com/en/news/290993657.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290993657.md)
generator: "portal-rs"
---

# Sunshine Lake Pharma Backs RMB2 Billion Healthcare and AI Venture Fund

An announcement from Sunshine Lake Pharma Co., Ltd. Class H ( (HK:6887) ) is now available.

Sunshine Lake Pharma has agreed with affiliates Shenzhen HEC Technology and Zhejiang HEC Health to establish a 12-year venture capital limited partnership fund focused on healthcare, biomedicine and artificial intelligence projects and sub-funds. The company will contribute RMB500 million, or 25% of the fund’s capital, financed from internal resources, while the HEC partners will provide the remaining RMB1.5 billion and oversee fund management.

The fund will invest in equity of unlisted companies and related assets, with profits and losses shared according to actual capital contributions and key decisions requiring unanimous partner approval, giving Sunshine Lake oversight rights despite its limited partner role. This structure is expected to broaden the company’s exposure to innovative healthcare and AI ventures, potentially enhancing its long-term growth prospects and strategic positioning in China’s evolving biomedical investment landscape.

**More about Sunshine Lake Pharma Co., Ltd. Class H**

Sunshine Lake Pharma Co., Ltd. is a pharmaceutical company based in mainland China, operating in the healthcare and biomedicine sector and listed in Hong Kong. The group focuses on drug development and related healthcare investments, leveraging partnerships and financial vehicles to expand its presence in emerging medical and technology-driven health fields.

**Average Trading Volume:** 404,598

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$19.61B

### Related Stocks

- [600673.CN](https://longbridge.com/en/quote/600673.CN.md)
- [06887.HK](https://longbridge.com/en/quote/06887.HK.md)

## Related News & Research

- [Guangdong HEC Pharma controlling shareholder Zhang lifts stake to 51.42% after buying 1,451,400 H shares for HK$56 million](https://longbridge.com/en/news/294357706.md)
- [Sunshine Lake Pharma Co: Revenue fell sharply and losses widened as core influenza drug sales declined, despite R&D and global expansion](https://longbridge.com/en/news/297490450.md)
- [CRET: Q2 2026 saw higher sales and improved margins, but growth is limited by financing constraints](https://longbridge.com/en/news/297468890.md)
- [Why Elon Musk Does NOT Want You to Know About These AI Bottlenecks](https://longbridge.com/en/news/298051407.md)
- [Microsoft survey finds 97% of healthcare leaders say data silos hinder timely care delivery](https://longbridge.com/en/news/297807480.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**